International Track 200

This Newcastle firm makes active ingredients and finished medicines for drug companies. The business, originally a pharmaceutical division of Boots, has grown by acquisition. It recently bought plants in Germany and Italy, and plans further expansion in North America and Asia. Most of its products are exported, with overseas sales reaching £158m in 2012. Silverfleet Capital backed a buyout from LDC, led by Aesica’s chief executive Robert Hardy, 54, in 2011.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
CompanyAesica Pharmaceuticals
ActivityPharmaceuticals manufacturer
2-yr av intl sales growth pa41.87%
International sales £000s*158,000
Total sales £000s*163,000

If applicable:

* Supplied by company † Annualised figure